FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316085017> ?p ?o ?g. }

• W4316085017 endingPage "e2008" @default.
• W4316085017 startingPage "e2007" @default.
• W4316085017 abstract "Introduction: Immunotherapy with immune checkpoint inhibitors (ICIs) has become the standard of care for many solid-organ and hematologic malignancies. Gastrointestinal toxicities are common side effects that typically occur 6 weeks after starting ICI therapy. Overlapping hepatotoxicity and colitis associated with ICIs is rare and may be overlooked, resulting in high mortality. Case Description/Methods: A 73-year-old man with metastatic squamous cell carcinoma (SCC) of the head and neck presented with intermittent, diffuse abdominal discomfort, bloating and painless non-bloody diarrhea (up to 6 episodes daily) triggered by meals. Symptom onset was 6 weeks after starting pembrolizumab for head and neck SCC. Pembrolizumab therapy was held, and supportive therapy with proton pump inhibitors, antacids and antidiarrheals provided partial symptom relief. Laboratory work up showed elevated AST 132 U/L, ALT 220 U/L, ALP 851 U/L and normal total bilirubin. ANA was elevated with titer 1:80, with normal total IgG (699.5 mg/dL) and negative serologies for anti-smooth muscle antibody, CMV, EBV, and HSV. Abdominal CT with contrast showed a dilated common bile duct (CBD) of 11 mm and a new curvilinear filling defect in the distal CBD, without choledocholithiasis. MRCP revealed mildly dilated intrahepatic biliary ducts, CBD dilation (13 mm), and an ovoid 8mm soft tissue nodule in the periampullary duodenum. Upper endoscopy was nondiagnostic. At this time, the patient’s symptoms improved, but there was high suspicion of grade-2 ICI-associated hepatitis (ICIH). Percutaneous liver biopsy showed interlobular bile duct injury with intraepithelial lymphocytes and neutrophils and a neutrophilic ductular reaction consistent with ICIH. Serial lab work demonstrated improvement of liver enzymes, with AST 77 U/L, ALT 69 U/L and ALP 667 U/L at 60 days after initial labs. Diarrhea resumed, up to 6 episodes per day, consistent with the Common Terminology Criteria for Adverse Events diagnosis of ICI-related colitis (ICIC). Initial supportive therapy failed to improve diarrhea; thus, a prednisone taper was started, resolving the colitis. He declined the option to resume immunotherapy and transitioned to comfort care (Figure 1). Discussion: Overlapping ICIH and ICIC is rare and may have discordance between symptomatology and lab findings. Early recognition of overlapping ICIH and ICIC, supportive treatment, permanent cessation of the inciting ICI and switching it with alternative immunosuppressive therapy may improve patient outcomes and quality of life.Figure 1.: Panel A - CT chest/abdomen with contrast (coronal view) showing common bile duct dilation of 1.2 cm (yellow calipers) status post cholecystectomy. Panel B. Upper endoscopy showing prominent ampulla with free-flowing bile. Panel C. Histology of percutaneous, ultrasound-guided liver biopsy with H&E staining (10×) shows preserved lobular hepatic architecture with mixed inflammatory infiltrate including lymphocytes, histiocytes, and scattered eosinophils expanding the portal tracts. Table 1. - Immune Checkpoint Inhibitor Associated Hepatitis Grades, adapted from the American Society of Clinical Oncology, 2021 Grade Criteria 1 Asymptomatic (AST or ALT > ULN to 3.0 X ULN and/or total bilirubin > ULN to 1.5 X ULN) 2 Asymptomatic (AST or ALT > 3.0 to ≤ 5 X ULN and/or total bilirubin > 1.5 to ≤ 3 X ULN) 3 AST or ALT 5-20 X ULN and/or total bilirubin 3-10 X ULN, OR symptomatic liver dysfunction; fibrosis by biopsy; compensated cirrhosis; and reactivation of chronic hepatitis 4 AST or ALT > 20 X ULN and/or total bilirubin > 10 X ULN OR decompensated liver function (e.g., ascites, coagulopathy, encephalopathy, and coma) Abbreviations: AST, aspartate transferase; ALT, alanine transaminase; ULN, upper limit of normal." @default.
• W4316085017 created "2023-01-14" @default.
• W4316085017 creator A5002220086 @default.
• W4316085017 creator A5018072236 @default.
• W4316085017 creator A5031254128 @default.
• W4316085017 creator A5065276856 @default.
• W4316085017 creator A5066650957 @default.
• W4316085017 creator A5076356266 @default.
• W4316085017 creator A5085878141 @default.
• W4316085017 date "2022-10-01" @default.
• W4316085017 modified "2023-10-16" @default.
• W4316085017 title "S3125 Overlapping Hepatotoxicity and Colitis Associated With Immune Checkpoint Inhibitors" @default.
• W4316085017 doi "https://doi.org/10.14309/01.ajg.0000869140.82532.c4" @default.
• W4316085017 hasPublicationYear "2022" @default.
• W4316085017 type Work @default.
• W4316085017 citedByCount "1" @default.
• W4316085017 countsByYear W43160850172023 @default.
• W4316085017 crossrefType "journal-article" @default.
• W4316085017 hasAuthorship W4316085017A5002220086 @default.
• W4316085017 hasAuthorship W4316085017A5018072236 @default.
• W4316085017 hasAuthorship W4316085017A5031254128 @default.
• W4316085017 hasAuthorship W4316085017A5065276856 @default.
• W4316085017 hasAuthorship W4316085017A5066650957 @default.
• W4316085017 hasAuthorship W4316085017A5076356266 @default.
• W4316085017 hasAuthorship W4316085017A5085878141 @default.
• W4316085017 hasBestOaLocation W43160850171 @default.
• W4316085017 hasConcept C121608353 @default.
• W4316085017 hasConcept C126322002 @default.
• W4316085017 hasConcept C160160445 @default.
• W4316085017 hasConcept C181199279 @default.
• W4316085017 hasConcept C185592680 @default.
• W4316085017 hasConcept C2777701055 @default.
• W4316085017 hasConcept C2777969384 @default.
• W4316085017 hasConcept C2779777945 @default.
• W4316085017 hasConcept C2780057760 @default.
• W4316085017 hasConcept C2780788601 @default.
• W4316085017 hasConcept C2780955771 @default.
• W4316085017 hasConcept C55493867 @default.
• W4316085017 hasConcept C71924100 @default.
• W4316085017 hasConcept C90924648 @default.
• W4316085017 hasConceptScore W4316085017C121608353 @default.
• W4316085017 hasConceptScore W4316085017C126322002 @default.
• W4316085017 hasConceptScore W4316085017C160160445 @default.
• W4316085017 hasConceptScore W4316085017C181199279 @default.
• W4316085017 hasConceptScore W4316085017C185592680 @default.
• W4316085017 hasConceptScore W4316085017C2777701055 @default.
• W4316085017 hasConceptScore W4316085017C2777969384 @default.
• W4316085017 hasConceptScore W4316085017C2779777945 @default.
• W4316085017 hasConceptScore W4316085017C2780057760 @default.
• W4316085017 hasConceptScore W4316085017C2780788601 @default.
• W4316085017 hasConceptScore W4316085017C2780955771 @default.
• W4316085017 hasConceptScore W4316085017C55493867 @default.
• W4316085017 hasConceptScore W4316085017C71924100 @default.
• W4316085017 hasConceptScore W4316085017C90924648 @default.
• W4316085017 hasIssue "10S" @default.
• W4316085017 hasLocation W43160850171 @default.
• W4316085017 hasLocation W43160850172 @default.
• W4316085017 hasOpenAccess W4316085017 @default.
• W4316085017 hasPrimaryLocation W43160850171 @default.
• W4316085017 hasRelatedWork W1991748699 @default.
• W4316085017 hasRelatedWork W2087847220 @default.
• W4316085017 hasRelatedWork W2142917855 @default.
• W4316085017 hasRelatedWork W2287493468 @default.
• W4316085017 hasRelatedWork W2351709420 @default.
• W4316085017 hasRelatedWork W2409195003 @default.
• W4316085017 hasRelatedWork W2978837168 @default.
• W4316085017 hasRelatedWork W2996913757 @default.
• W4316085017 hasRelatedWork W3041961515 @default.
• W4316085017 hasRelatedWork W3128553508 @default.
• W4316085017 hasVolume "117" @default.
• W4316085017 isParatext "false" @default.
• W4316085017 isRetracted "false" @default.
• W4316085017 workType "article" @default.